Floatz logo

Therapeutic Asset Ratings

6,299 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Dual-Target Antigen-Selected Car-Nk
Non-Hodgkin Lymphoma
Essen BiotechP1/2CC (45)
Dual-Target Car-Nk Cells
Gastric Adenocarcinoma
Beijing BiotechP1/2CC (45)
Dual-Target Car-Nk Cells
Breast Cancer
Beijing BiotechP1/2CC (45)
Durvalumab
Childhood Malignant Neoplasm
AstraZenecaP1/2CC (45)
Durvalumab
Mycosis Fungoides
City of Hope Medical CenterP1/2CC (45)
Durvalumab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
City of Hope Medical CenterP1/2CC (45)
dyp688
Uveal Melanoma
Novartis PharmaceuticalsP1/2CC (45)
e7386
Endometrial Cancer
Eisai Inc.P1/2CC (45)
e7386
Liver And Intrahepatic Bile Duct Neoplasm
Eisai Inc.P1/2CC (45)
eb103
Primary Central Nervous System Lymphoma
Estrella Biopharma, Inc.P1/2CC (45)
Eb-Dnk101 Dual-Targeting Car-Nk Cells
Metastatic Neoplasm
Beijing BiotechP1/2CC (45)
Ebnk-001
Cutaneous Melanoma
Essen BiotechP1/2CC (45)
Ebnk-001
Malignant Pancreatic Neoplasm
Essen BiotechP1/2CC (45)
Eb-Select Single-Target Car-Nk Cells
Acute Myeloid Leukemia
Essen BiotechP1/2CC (45)
Eb-Select Single-Target Car-Nk Cells
Cutaneous Melanoma
Essen BiotechP1/2CC (45)
Eb-Select Single-Target Car-Nk Cells
Non-Hodgkin Lymphoma
Essen BiotechP1/2CC (45)
ect204 t cells
Liver Cancer
Eureka Therapeutics Inc.P1/2CC (45)
Edv-Gc
Pancreatic Ductal Adenocarcinoma
Engeneic Pty LimitedP1/2CC (45)
E-Edv-D682
Pancreatic Ductal Adenocarcinoma
Engeneic Pty LimitedP1/2CC (45)
Eflornithine
Diffuse Midline Glioma, H3 K27M-Mutant
Aminex Therapeutics, Inc.P1/2CC (45)
Eflornithine
Malignant Glioma
Mayo ClinicP1/2CC (45)
Eflornithine
Cutaneous Melanoma
Aminex Therapeutics, Inc.P1/2CC (45)
Egfr Fpbmc
Pancreatic Neoplasm
University of VirginiaP1/2CC (45)
eik1004-001
Cancer
Eikon TherapeuticsP1/2CC (45)
Emavusertib
Refractory Hematologic Cancer
Curis, Inc.P1/2CC (45)
Showing 3526 to 3550 of 6,299 assets
PreviousPage 142 of 252Next